Intellectual property law firm Spicer Spicer has lost its opposition to Coca-Cola’s patent application for soft drinks and syrups containing an artificial sweetener known as Reb X, with an IP Australia delegate rejecting the firm’s argument the patent was not inventive.
US-based chemical and materials technology company Cytec Industries has won its Federal Court challenge to a mining patent application by a unit of Ecolab, with the court finding the claims in the patent lacked support and sufficient disclosure.
Property data analytics firm CoreLogic infringed the copyright of a real estate photographer by uploading images from realestate.com.au to its own property data platform without a licence, the Full Federal Court has found.
New-Zealand dairy company a2 Milk is challenging a win for Nestle over the Swiss food and drink giant’s NAN A2 trade mark for infant formula, a mark IP Australia found was not deceptively similar to a2’s logo.
Australian menswear label yd. has been sued for “blatant and obvious” copyright infringement for allegedly using a floral pattern produced by rival brand Politix on its shirts.
The maker of Finish dishwashing products is seeking an urgent injunction to clear a competitor’s products from supermarket shelves, alleging trademark infringement over “deceptively similar” packaging depicting dishwasher gel caps.
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
The right approach to determining patentability of a computer-implemented invention is to first assess whether it is more than a mere scheme or business method, the Full Federal Court has been told in an appeal of a ruling backing IP Australia’s revocation of two patents by plumbing company Repipe.
Service station giant Ampol has lost its bid to force petrol station chain EG Fuel Co to allow it access to 87 Caltex sites so they can be rebranded to Ampol stations, with a judge finding it would cause EG “obvious disruption”.
Swiss pharmaceutical company Biogen has filed another lawsuit accusing an Australian generic drug manufacturer of infringing the patent for its blockbuster multiple sclerosis drug Tecfidera.